Imagine a high-tech ultrasound wand that can 'see' white blood cells in body fluids without needing a needle. Instead of a painful spinal tap for babies, this device scans through the soft spot on a newborn's head to find signs of meningitis. It uses smart software to count the cells automatically, making the process as simple as a quick scan.
Detecting infant meningitis currently requires invasive lumbar punctures, which are risky and cost-inefficient. There is a critical need for a non-invasive, rapid screening tool to prevent life-long disabilities or death in newborns.
A hand-held high-resolution ultrasound device and AI algorithms for counting white blood cells. Additionally, a diagnostic software was developed to estimate pathogen types (virus vs bacteria).
If you are a hospital dealing with the risks and costs of invasive lumbar punctures for infants — this project developed a hand-held ultrasound device that detects meningitis with 100% sensitivity. This allows doctors to limit invasive procedures to only a few patients.
If you are a clinic dealing with the slow validation of peritonitis in domiciliary peritoneal dialysis patients — this project developed a screening tool that enables rapid validation. This reduces regulatory risks and opens a large market opportunity for early infection detection.
If you are a clinic dealing with the difficulty of quantifying uveitis severity — this project developed a non-invasive ultrasound and AI system. It provides accurate quantification of the infection's degree of severity without invasive sampling.
Based on available project data, the company is currently working on minimizing and optimizing costs linked to key components, but specific pricing is not disclosed.
Yes, the company is currently selecting partners for device manufacture, consumables production, packaging, and shipping to achieve complete industrialization.
The project is based on a patented first-in-class medical device, suggesting strong IP protection for the ultrasound and AI counting technology.
The project is working toward CE marking for the device to allow for market launch in the peritoneal dialysis, infant meningitis, and uveitis segments.
The project period runs until 2025-08-31, with the peritoneal dialysis market targeted for launch first, followed shortly by meningitis and uveitis applications.
The project is led by a single Spanish SME, NEOS NEW BORN SOLUTIONS SL, with a 100% industry ratio. This lean structure indicates a highly focused commercial drive, as the company is managing everything from AI development to the selection of manufacturing and shipping partners internally.
Contact NEOS NEW BORN SOLUTIONS SL in Spain
Contact us to explore licensing or partnership opportunities for this AI-ultrasound technology.
